Australia Veterinary Market 2026 | Worth USD 4.9 Billion by 2034

Australia Veterinary Market Overview:
Australia's veterinary market is witnessing accelerated growth, driven by rising pet ownership across 73% of households with 31.6 million pets, increasing humanization of companion animals, and rapid technology adoption including AI-powered diagnostics and telehealth. Therapeutics lead the market with a 60.58% share, while diagnostics represent the fastest-growing segment as preventive care becomes the norm. Pet owners now spend over AUD 33 billion annually on their animals, with premium veterinary procedures exceeding AUD 10,000 becoming increasingly common. The Australia veterinary market size reached USD 2.1 Billion in 2025. Looking forward, the market is projected to reach USD 4.9 Billion by 2034, exhibiting a growth rate (CAGR) of 9.60% during 2026-2034. The market spans therapeutics including vaccines, parasiticides, and anti-infectives alongside diagnostics such as immunodiagnostic tests, molecular diagnostics, and diagnostic imaging across companion animals, equine, livestock, and poultry segments. EQT's acquisition of VetPartners creating a 267-clinic network, CVS Group's USD 82.5 million investment in 28 Australian sites, Zoetis's Melbourne vaccine plant expansion, and the rollout of AI clinical tools across more than 140 practices are among the key developments reshaping the industry.

Read more about Australia Veterinary Market https://www.imarcgroup.com/australia-veterinary-market/

Australia Veterinary Market Summary:
• Australia is home to approximately 31.6 million pets across 73% of households, a significant jump from 69% in 2022 and 61% before the pandemic. Dogs remain the most popular companions at 48% of pet-owning homes, followed by cats at 33%. This expanding pet population is the primary engine behind sustained veterinary service demand, with annual pet-related spending exceeding AUD 33 billion nationwide.

• Therapeutics dominate the market with a 60.58% share, underpinned by strong demand for vaccines, parasiticides, and anti-infective treatments across both companion and production animals. Australia's geographic diversity and tropical northern regions create persistent parasitic disease pressure that drives regular treatment cycles, while national vaccination programs for livestock contribute steady revenue streams.

• The diagnostics segment is growing fastest, fueled by a shift toward preventive and early-detection care. Molecular diagnostics, immunodiagnostic tests, and advanced imaging technologies are becoming standard in urban practices. Investment in veterinary telemedicine and diagnostic tools has increased by 21%, reflecting a sector-wide pivot from reactive treatment to proactive health management.

• Private equity consolidation is reshaping the industry landscape. EQT's acquisition of VetPartners created a 267-clinic network employing more than 1,300 veterinarians, while UK-based CVS Group invested USD 82.5 million to secure 28 Australian sites. Greencross, valued at approximately USD 3.75 billion, is evaluating an ASX relisting to fund digital initiatives and clinic refurbishments.

• Telehealth is gaining meaningful traction, with veterinary telehealth consultations projected to increase by 31%. Dial A Vet, Australia's leading veterinary telehealth service, is offering 24/7 access to licensed veterinarians for AUD 25 per consultation, extending care to 7 million households. Early pilots show emergency-visit frequency falling 15-20% when insurers incentivize online consultations.

• AI-powered tools are transforming clinical workflows and diagnostic accuracy. Heidi Health's AI platform has been deployed across more than 140 general practices and 24 specialty hospitals, automatically generating clinical records during consultations and reducing administrative burden. The global AI-powered veterinary diagnostics market is expanding at over 20% annually, and Australian clinics are early adopters.

• A persistent veterinary workforce shortage remains a critical challenge, particularly in regional and remote areas. The pet-to-vet ratio stands at roughly 1,908 to 1, creating referral bottlenecks and contributing to burnout among practitioners. The concentration of specialists in urban clusters leaves rural communities underserved, driving demand for telehealth and mobile clinic solutions.

• Zoetis purchased a 21-acre Melbourne plant to double its vaccine production output, aligning with government calls for domestic manufacturing capability. This investment reflects the broader trend of multinational animal health companies expanding their Australian footprint to serve both domestic demand and the broader Asia-Pacific region.

Request for a sample report PDF: https://www.imarcgroup.com/australia-veterinary-market/requestsample

Key Trends Shaping the Australia Veterinary Market:
Pet Humanization and Premium Veterinary Spending: Australian pet owners are increasingly treating animals as family members, driving demand for advanced surgical procedures, oncology treatments, and specialist referrals that routinely exceed AUD 10,000 per case. This humanization trend extends to preventive health plans, dental care, and behavioral consultations, pushing average veterinary spending per household well above pre-pandemic levels and supporting practice revenue growth across both metropolitan and suburban clinics.

Telehealth Expansion and Digital-First Veterinary Care: Veterinary telehealth is emerging as a viable frontline service channel, with consultations projected to rise by 31% as platforms like Dial A Vet offer 24/7 access at AUD 25 per session. Remote triage, asynchronous follow-ups, and AI-assisted symptom checkers are extending care reach to regional and remote communities where the veterinary workforce shortage is most acute, while insurance pilots show 15-20% reductions in emergency visit frequency through virtual first-contact models.

Private Equity-Driven Clinic Consolidation: The Australian veterinary sector is undergoing rapid consolidation as private equity firms pursue scale economies. EQT's VetPartners acquisition created a 267-clinic network, CVS Group committed USD 82.5 million to 28 local sites, and Greencross is considering a public relisting valued near USD 3.75 billion. This consolidation wave is standardizing clinical protocols, centralizing procurement, and investing in technology upgrades across networked practices.

AI-Powered Diagnostics and Clinical Automation: Artificial intelligence is reshaping veterinary diagnostics and practice management. Tools like Heidi Health are deployed in over 140 practices to auto-generate clinical records, while AI-powered imaging and pathology platforms are improving diagnostic accuracy and speed. The global AI veterinary diagnostics market is growing at over 20% annually, with Australian clinics at the forefront of adoption due to strong digital infrastructure and tech-savvy practice owners.

Domestic Manufacturing and Biosecurity Investment: Australia is strengthening its domestic animal health manufacturing base, highlighted by Zoetis's 21-acre Melbourne plant acquisition to double vaccine production. This aligns with federal government priorities around biosecurity and supply chain resilience, ensuring that critical veterinary medicines and biologics can be produced locally rather than relying on imports. The APVMA continues to modernize regulatory pathways to support faster market access for new veterinary products.

Australia Veterinary Market Growth Factors:
Expanding Pet Population and Rising Companion Animal Healthcare Expectations
Australia's pet population has expanded to 31.6 million animals across 73% of households, marking a substantial increase from 61% before the pandemic. This growing base translates directly into higher veterinary service utilization as owners invest in vaccinations, parasite prevention, dental cleanings, and wellness check-ups that were once considered discretionary. Annual pet-related expenditure has surged to over AUD 33 billion, with a meaningful share directed toward veterinary services, diagnostics, and prescription therapeutics. The cultural shift toward viewing pets as family members means owners are willing to fund complex surgical interventions, chronic disease management, and specialist referrals, providing a durable growth runway for the veterinary sector.

Technology Adoption Reshaping Veterinary Service Delivery
The Australian veterinary industry is rapidly embracing digital transformation, with investment in telemedicine and diagnostic tools rising by 21%. Telehealth platforms like Dial A Vet now provide round-the-clock access to licensed veterinarians for AUD 25 per consultation, reaching 7 million households and bridging the care gap in underserved regions. AI clinical tools, notably Heidi Health's automated record-generation system deployed across more than 140 practices and 24 specialty hospitals, are reducing administrative burden and freeing clinicians to focus on patient care. The global AI-powered veterinary diagnostics market is growing at over 20% annually, and Australian practices are benefiting from improved imaging accuracy, faster pathology turnaround, and data-driven treatment recommendations that enhance outcomes and client satisfaction.

Industry Consolidation and Strategic Capital Deployment
Private equity investment is catalyzing structural change across the Australian veterinary landscape. EQT's acquisition of VetPartners, finalized in early 2025, created a 267-clinic network employing more than 1,300 veterinarians with intensified supplier bargaining power and accelerated protocol standardization. CVS Group's USD 82.5 million investment in 28 Australian sites signals sustained cross-border interest in the market, while Greencross evaluates an ASX relisting at a valuation near USD 3.75 billion to unlock capital for digital transformation and facility upgrades. On the manufacturing side, Zoetis purchased a 21-acre Melbourne plant to double vaccine output, aligning with government priorities around biosecurity and domestic supply chain resilience. These combined capital flows are modernizing infrastructure, improving clinical standards, and creating integrated care networks.

Australia Veterinary Market Segmentation:
By Product:
• Therapeutics (Vaccines, Parasiticides, Anti Infectives, Medical Feed Additives, Others)
• Diagnostics (Immunodiagnostic Tests, Molecular Diagnostics, Diagnostic Imaging, Clinical Chemistry, Others)

By Animal Type:
• Dogs and Cats
• Horses
• Ruminants
• Swine
• Poultry
• Others

By Region:
• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

Australia Veterinary Market Key Players:
The Australia veterinary market is shaped by a mix of global animal health corporations, private equity-backed clinic networks, and domestic specialty companies. Key players include Zoetis Inc., VetPartners Australia (EQT), Greencross Limited, CVS Group plc, Elanco Animal Health, Boehringer Ingelheim, Idexx Laboratories, Merck Animal Health (MSD), Virbac Australia, and Dechra Pharmaceuticals. These companies are driving innovation through product development, clinic network expansion, digital health solutions, and domestic manufacturing investments.

Key Aspects Required for the Australia Veterinary Market:
• Addressing the veterinary workforce shortage through expanded university intake, streamlined visa pathways for overseas-trained veterinarians, and investment in rural placement incentives to reduce the 1,908:1 pet-to-vet ratio.

• Scaling telehealth infrastructure to provide equitable veterinary access across regional and remote Australia, leveraging platforms like Dial A Vet that offer 24/7 consultations at affordable AUD 25 rates.

• Integrating AI-powered clinical automation tools such as Heidi Health into standard practice workflows to reduce administrative burden, improve diagnostic accuracy, and allow veterinarians to focus on patient-facing care.

• Strengthening domestic manufacturing capacity for veterinary medicines and biologics, building on investments like Zoetis's Melbourne plant expansion, to reduce import dependency and support biosecurity objectives.

• Modernizing APVMA regulatory pathways to accelerate market access for new veterinary therapeutics and diagnostics while maintaining rigorous safety and efficacy standards.

• Developing comprehensive pet insurance penetration strategies that incentivize preventive care and telehealth utilization, following pilot models showing 15-20% reductions in emergency visit frequency.

• Ensuring that private equity-driven consolidation benefits both practice standards and practitioner wellbeing, with attention to workload management, career development pathways, and fair compensation across networked clinics.

• Expanding clinical training programs in advanced diagnostics, molecular testing, and AI-assisted imaging to upskill the existing workforce and meet growing demand for precision veterinary medicine.

Recent News and Developments:
January 2025: EQT completed its acquisition of VetPartners Australia, creating a 267-clinic network employing more than 1,300 veterinarians. The deal intensifies supplier bargaining power and is expected to accelerate clinical protocol standardization across the network.

March 2025: The Australian Veterinary Association released updated policies addressing veterinarians' role in Aboriginal and Torres Strait Islander community dog and cat health management programs, alongside new sustainability guidelines for companion animal practice.

May 2025: The Pets in Australia 2025 national survey confirmed pet ownership had risen to 73% of households with 31.6 million animals, up from 69% in 2022, reinforcing the sustained demand trajectory for veterinary services across all states and territories.

June 2025: CVS Group committed USD 82.5 million to acquire 28 veterinary practice sites across Australia, marking the UK-based consolidator's largest single investent in the Australian market and intensifying competition among multi-site operators.

July 2025: VetPartners Australia completed a buyout of Pet Chemist Online, expanding its service offering beyond clinical care into the growing pet pharmacy and wellness product segment, diversifying revenue streams across its clinic network.

August 2025: Zoetis finalized the purchase of a 21-acre manufacturing facility in Melbourne to double its Australian vaccine production capacity, aligning with federal government priorities around biosecurity and domestic supply chain resilience.

October 2025: Dial A Vet announced nationwide expansion of its veterinary telehealth platform, offering 24/7 access to licensed veterinarians at AUD 25 per consultation for 7 million Australian households, with a focus on bridging care gaps in regional and remote areas.

December 2025: The APVMA published its updated Veterinary Medicines Regulatory Newsletter outlining streamlined registration pathways for novel therapeutics and diagnostics, supporting faster market access while maintaining safety and efficacy standards for veterinary products.

Note: If you require any specific information not currently covered within the scope of the report, IMARC Group will provide it as part of customization.
Speak to an analyst:
https://www.imarcgroup.com/request?type=report&id=28830&flag=E

Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-631-791-1145

About Us:
IMARC Group is a global management consulting firm that helps companies in achieving growth in the international marketplace. We offer advisory and market intelligence services in the areas of technology, healthcare, consumer products, food and beverages, chemicals and materials, and several other sectors. We also help venture capitalists, private equity firms, and investment banks in evaluating companies across the globe. Our research reports are available across 150+ countries and are recognized by Fortune 500 companies, top management consulting firms, and venture capital firms. IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. We also offer consulting services to help organizations from the strategic planning to the implementation stage. For more information, please visit the IMARC Group website.

This release was published on openPR.